NYSE:EW - Edwards Lifesciences Stock Price, Forecast & News

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences shares split on the morning of Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly minted shares were issued to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

Edwards Lifesciences Corp (NYSE:EW) issued its quarterly earnings results on Thursday, January, 30th. The medical research company reported $1.46 EPS for the quarter, missing analysts' consensus estimates of $1.49 by $0.03. The medical research company earned $1.17 billion during the quarter, compared to the consensus estimate of $1.15 billion. Edwards Lifesciences had a net margin of 24.08% and a return on equity of 31.73%. The firm's quarterly revenue was up 20.1% on a year-over-year basis. During the same period in the previous year, the company posted $1.17 EPS. View Edwards Lifesciences' Earnings History.

Edwards Lifesciences is scheduled to release their next quarterly earnings announcement on Tuesday, April 28th 2020. View Earnings Estimates for Edwards Lifesciences.

Edwards Lifesciences updated its FY20 earnings guidance on Thursday, January, 30th. The company provided earnings per share (EPS) guidance of $6.15-6.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.98. The company issued revenue guidance of $4.6-5.0 billion, compared to the consensus revenue estimate of $4.70 billion.

22 Wall Street analysts have issued 1-year price objectives for Edwards Lifesciences' shares. Their forecasts range from $159.00 to $300.00. On average, they anticipate Edwards Lifesciences' share price to reach $250.38 in the next twelve months. This suggests a possible upside of 17.6% from the stock's current price. View Analyst Price Targets for Edwards Lifesciences.

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 3 sell ratings, 5 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Edwards Lifesciences.

News articles about EW stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Edwards Lifesciences earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future. View News Stories for Edwards Lifesciences.

Edwards Lifesciences saw a decrease in short interest in February. As of February 14th, there was short interest totalling 2,040,000 shares, a decrease of 14.3% from the January 30th total of 2,380,000 shares. Based on an average trading volume of 1,280,000 shares, the short-interest ratio is currently 1.6 days. Currently, 1.0% of the shares of the company are sold short. View Edwards Lifesciences' Current Options Chain.

Some companies that are related to Edwards Lifesciences include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX), Varian Medical Systems (VAR) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Walt Disney (DIS), Home Depot (HD), Visa (V), Mastercard (MA), Broadcom (AVGO), UnitedHealth Group (UNH) and Gilead Sciences (GILD).

Edwards Lifesciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (4.28%), FMR LLC (3.88%), Bank of New York Mellon Corp (2.97%), Sands Capital Management LLC (2.91%), Jennison Associates LLC (2.35%) and Capital Research Global Investors (2.24%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.

EW stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Jennison Associates LLC, Alliancebernstein L.P., Thrivent Financial for Lutherans, Marshall Wace North America L.P., Bank of New York Mellon Corp, Bessemer Group Inc. and Partner Fund Management L.P.. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.

EW stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, FMR LLC, UBS Asset Management Americas Inc., Amundi Pioneer Asset Management Inc., Prudential Financial Inc., William Blair Investment Management LLC, Captrust Financial Advisors and Skandinaviska Enskilda Banken AB publ . View Insider Buying and Selling for Edwards Lifesciences.

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EW stock can currently be purchased for approximately $212.96.

Edwards Lifesciences has a market capitalization of $44.53 billion and generates $4.35 billion in revenue each year. The medical research company earns $1.05 billion in net income (profit) each year or $5.57 on an earnings per share basis. Edwards Lifesciences employs 13,900 workers across the globe.View Additional Information About Edwards Lifesciences.

The official website for Edwards Lifesciences is http://www.edwards.com/.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]